Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T07:58:53.628Z Has data issue: false hasContentIssue false

VILOXAZINE

Published online by Cambridge University Press:  03 April 2024

Stephen M. Stahl
Stephen M. Stahl
Affiliation:
University of California, San Diego and Riverside
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide
Stahl's Essential Psychopharmacology
 , pp. 885 - 890
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Faraone, SV, Gomeni, R, Hull, JT, et al. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res 2021;296:113664.CrossRefGoogle ScholarPubMed
Nasser, A, Liranso, T, Adewole, T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther 2021;43(4):684–700.CrossRefGoogle ScholarPubMed
Pliszka, S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894–921.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • VILOXAZINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.150
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • VILOXAZINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.150
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • VILOXAZINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.150
Available formats
×